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Early detection and diagnosis improve both the management and the survival ot patients with prostate cancer.
The PSA is an excellent tool in urologist's hand, can help in early detection of prostate cancer, in the follow up of the medical treat­
ment or after radical prostatectomy with the purpose of checking the effectiveness ot the treatment. On the other hand, the PSA can 
result in unnecessary biopsies, causing patient's anxiousness, therefore bearing both advantages and disadvantages. One has to learn 
and be familiar with the evaluation of the PSA concentration, as well as different PSA derivatives such as PSA velocity, PSA densi­
ty and free PSA level.
PSA should not only be performed in patients with prostate cancer, but also for screening purposes, in combination with rectal digi­
tal and transrectal ultrasound examination.
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Diagnosing prostate cancer seemed to be "simple" 30 or 40 years 
ago, since we diagnosed it by digital rectal exam. After this, we 
carried out castration and the patient was administered a terrible 
amount of estrogen hormone (cca 20-25 mg). As a consequence, 
he died either due to the tumorous disease or the side effects of 
our treatment. In the case of false positive rectal exam, the treat­
ment turned out to be false as well...
The beginning
The discovery of PSA was an extremely important event in our 
clinical practice, however we were not aware of its importance 
at that time. I was working in West Germany in the middle ot 
1980s when the measurement of PSA was clinically introduced
- still surrounded by many doubts. We carried out prostate biop­
sy (not too often) and had to rely on its results. We also record­
ed the PSA levels; however only afterwards, since it was first 
measured every other week - later weekly.
After collecting the cases where we measured PSA, I presented 
a poster on the topic at the European Urology Conference in 
London in 1988; following this conference I presented the same 
poster at a Hungarian Congress - however, few were interested. 
Also in the same year I was given reagents for carrying out 100 
examinations, therefore we started to use them at our hospital.
We did not really know which groups of patients we had to 
involve and we had troubles with assessing the results as well. 
Moreover, we lacked patients, so we needed to get serums from 
other hospitals. My boss was not really certain about PSA 
either...
For all this, we managed to publish the first Hungarian study on 
PSA examinations at our department in Orvosi Hetilap (1) 
(Medical Weekly). Following this event we succeeded in organ­
izing an international conference in the Hotel Geliert Budapest 
in 1991. Thanks to our efforts, the use of PSA examinations
started to spread. Hence, in 2007 there were 5000 PSA exami­
nations at Semmelweis University, most of which were indicat­
ed by urologists. Since then assessing PSA has become a daily 
linical practice.
Indications
In what cases should PSA be determined?
• For medical check-ups, at male patients without symptoms 
(not financed by the Hungarian insurance).
• In the case of positive rectal palpation.
• In the case of negative rectal exam, but the patient has fre­
quency.
• If the patient has already been treated with alpha receptor 
inhibitors due to the complaints of benign prostate hyperpla­
sia, but there are still symptoms.
• If PSA level - checked after a three month interval - is 
increasing.
• Bone pains, in the case of tumor suspected X-ray or isotop 
scan.
• In the case of a patient with prostate cancer (without p. histo­
ry) to follow up the effectiveness of the treatment.
• After radical prostatectomy, PSA levels could provide us 
information of the biochemical failure of disease.
• The list of indications seems to be long, but do patients 
always benefit from this examination?
• During general medical check-ups the rate of diagnosing 
prostate tumors is very low, therefore it is not economical. 
However, those recognized at an early stage will definitely 
recover.
Moreover, the effectiveness of PSA is better than 
colonoscopy and its sensibility is high above other tumor 
markers. There was, however, an editorial article published in 
the European Urology where it was noted that "The PSA era 
and its challenges are not over." (2)
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Throughout rectal examination local tumors can be detected in 
30% of cases. Therefore, rectal digital examination is not capa­
ble of detecting all the tumors at an early stage without PSA 
examination. We cannot, however, apart from the practice!
PSA level, what should we do with it?
What level is positive in fact?
Higher levels (> 3 or > 4 ng/ml) than the level authorized by the 
laboratory?
This is not true in this way. Regardless of the higher PSA levels 
(4-10 ng/ml) which were measured at our patients, tumors were 
detected only in 20-40 % by biopsy. Biopsy is said to be unnec­
essary in 60-80%. Unnecessary? The number of tumorous 
patients with normal PSA levels could reach up to 15% (3). This 
means that prostate tumor could occur at those patients who have 
normal PSA levels (> 2.5 ng/ml) (4). In the case of bone metas­
tasis of prostate cancer, which causes pain to the patients, we can 
definitely be sure of finding an increased level of PSA. However, 
if we detect a suspicious shadow on the X-ray image besides 
normal PSA levels, prostate cancer or at least metastasis could 
likely be excluded. Furthermore, in the case of proved malignant 
disease the follow-up of PSA level is inevitable. However, we 
can face surprising events is the case of hormone resistance: 
tumorous progression may occur besides normal PSA levels, as 
well, furthermore, increasing PSA levels during hormone treat­
ment should indicate change in drug treatment. It is also impor­
tant to know that cycling, horse riding, ejaculation or even rectal 
examination before blood test will increase PSA levels. 
Finasterid (drug) administered due to prostate hypertrophy will 
decrease PSA levels by 50%.
Annoying factors
PSA level arises in accordance with patient's age. At the age of 
45, the normal figure is 2.5 ng/ml, whereas at the age of 80 it 
might be 6,5 ng/ml. This is, however, not always true. 30% of 
patients between the age of 70-80 have the PSA level under 3 
ng/ml (Table 1) Moreover, PSA level arises is accordance with 
the prostate volume. It could be true since an enlarged prostate 
might indicate an increased PSA level. The calculation of PSA 
density (PSA divided by prostate volume) might help us to avoid 
mistakes. The problem is, however, that calculating proper 
prostate volume seems to be difficult. In addition PSA level 
increases in the case of prostate inflammation. This higher level 
of PSA could be detected three months later, as well, in the 30% 
of the cases. The pathological level can be normalized only after 
6 months, if treated properly. Therefore, in the case of a patient 
with chronic prostatitis, several biopsies might be performed 
because of an increased PSA level if the prostatitis is symptom- 
free and the urologist does suspect a chronic inflammation. 
Nevertheless, the biopsy results do not always describe inflam­
mation since the pathologist usually searches for tumorous dis­
ease as indicated by the examining urologist. Therefore, in the 
case of suspected prostatitis causing higher PSA levels, biopsy 
should be preceded by an antibiotic treatment. As a consequence, 
the number of unnecessary biopsies could be reduced. We could 
suspect chronic prostate inflammation in the case of pyuria after 
a massage, however, the lack of pyuria would not definitely 
exclude prostatitis. The diurinal change of PSA might reach 10- 




What should we do with the patient whose PSA levels are steadi­
ly increasing but the biopsies are all negative? The reason could 
either be traced in the patient or in the method of biopsy. One 
reason can be the inflammation explained before, for instance in 
the case of prostate stones (which normally should not be treat­
ed) occurs a perifocal inflammation. The method of performing 
biopsy might provide us reasons. It is no use mentioning those 
cases where the biopsy sample cannot be analyzed and assessed. 
In this case, the urologist is informed of the insufficient sample, 
and the pathologist does not give any opinion. There are few 
biopsies performed without ultrasound guidance, however, biop­
sies taken in this way are rather leading to inadequate results. On 
the contrary, ultrasound guided biopsy might provide us insuffi­
cient samples. For example, the pathologist is not aware of 
which part of the prostate the samples are taken from, therefore, 
in the case of two samples taken very close from each other the 
pathology result might be misleading since cancer could be hid­
den in the untouched part of the prostate. In addition, the sample 
can be too short, too crumpled, or the pathologist can also make 
mistakes, even when he is a beginner, or he works at an institu­
tion where there are few urological samples. If voiding symp­
toms are not better regardless of alpha inhibitors, we have to 
think of tumors. Also we can think of the fact that the patient 
does not take the drug regularly or of a progressed stage where 
the administered drug is not having a proper effect and therefore 
the patient's status is not getting better. The annual increase in 
PSA level is 0.17 ng/ml, thus in the case of a higher annual level, 
biopsy is definitely indicated (5).
Radical surgery
The radical prostatectomy is a curative treatment. We remove the 
prostate, the seminal vesicle and often the regional lymph nodes 
as well. This latter treatment is not necessary under 10 ng/ml, but 
we usually perform this surgery. We try to cut through the ure­
thra under the apex, then we remove it from the bladder cervix 
in order not to leave any prostate tissue there. The proof of our 
success is the PSA level of 0.0 ng/ml 8 weeks after the surgery. 
However, in the 30% of the cases, PSA level can be detected 10 
years after the surgery (biochemical failure). If there is a prostate 
tissue remained, PSA level can be detected 8 weeks after the sur­
gery, however, this is rather rare. Biochemical failure occurs 
more often in those patients who had higher PSA levels before 
the surgery (let’s call it 25 ng/ml) or when the tumor infiltrated 
the capsule (stage more than pT2) and the Gleason score is high 
(more than 8). But why will some patients have detectable PSA 
levels 3-5 years after the surgery? I truly do not know... Nobody 
knows...
Blessing or curse?
PSA is a blessing for those whose cancer was detected in an 
early stage.
PSA is a curse for those whose prostate cancer is recognized in 
an early stage, but during the histology examination the tumor 
was not significant (< 0.2 cm3); the patient might have lived 
without any symptoms for a long time - but he had to undergo a 
surgery with all its side effects and complications.
Imre Romics: Prostate Specific Antigen: Blessing or Curse?
Med Vjesn 2008; 40(1-4): 45-48
PSA is a curse for those whose PSA level is higher (more than 4 
ng/ml) and his prostate is bigger (for example 80 g) which might 
explain higher PSA level; however since the doctor as well as 
the patient has in doubts, biopsy will surely be performed.
PSA is a blessing for that patient, who had been checked for 6-8 
years, many biopsies were performed and finally he was cured 
with brachytherapy at the age of 74.
PSA is a curse for the patient who underwent a surgery even 
though his tumor was local and became incontinent. The correc­
tion surgery, however, was successful.
PSA is a blessing for that 52-year-old father with three children, 
who after undergoing the surgery became tumor-free, moreover 
taking VIAGRA ®, he became potent as well. (His PSA is 0.0 
ng/ml now).
PSA is a curse for all those patients where biopsy was performed 
just because of an increased PSA level. They are waiting for the 
adoption to the hospital, waiting for the histology results - mean­
while they are being nervous. If the PSA is positive, they become 
more nervous, if it is negative, they still remain anxious about he 
results (6).
PSA is a blessing for the man who has a zero level PSA, symp­
tom-free and even more he remains potent. This is the so-called 
"trifecta", which we are struggling to achieve. How could we 
apart from these paradoxes? We cannot put PSA aside, since 
there is no better solution regardless of all the critical remarks. 
In the USA, 80-100 of the male patients want to know the level 
of PSA, whereas this number is only 30-50% in Europe (3).
What can we do?
We have to consider PSA level very important. Examine the 
patient carefully (rectally, transvesical US or by MR examina­
tion). Control the examination (is it not after a massage, etc?) in 
order to get closer to the real PSA level. If we have doubts about 
the results, we have to repeat the test. In the case of suspected 
prostatitis, administrate antibiotics and antiphlogistics promptly, 
and check PSA afterwards. The treatment is the same if the 
inflammation is proved. We should measure the residuum after 
voiding, if the volume is higher, we can allow for an increased 
PSA level. The blood should be taken before rectal examination. 
We can dream of a new marker - which exists already PC3, by 
which we can make diagnosis after massage. We are also taking 
part in a study (7) with experts from London and Bruxelles, 
throughout which we try to set up diagnosis via three dimen­
sional transrectal ultrasound examination. We should patiently 
wait for the new results - 
I hope to inform you about them afterwards...
REFERENCES
1. Romics I, Bach D. Our experiences in prostate cancered patients
obtained by PSA (in Hungarian: A prostataspecifikus antigennel szerzett
tapasztalataink prostatadaganatos betegekben.) Orv Hetil. 
1989;130:2797-800.
2. Shariat SF, Karakiewicz PI. Screening for prostate cancer in 2007: the 
PSA era and its challenges are not over. Eur Urol. 2007;53:457-60.
3. Reed A, Ankerst DP, Pollock BH, Thompson IM, Pareks DJ. Current
age and race adjusted prostate specific antigen threshold values delay
diagnosis of high grade prostate cancer. J Urol. 2007;178(5): 1929-32.
4. Giri VN, Beebe-Dimmer J, Buyyounonski M, Konski A, Feigenberg SJ, 
Uzzo RG, i sur. Prostate cancer risk assessment program: a 10-year 
update of cancer detection. J Urol. 2007; 178(5): 1920-4.
5. Loeb S, Roehl KA, Nadler RB, Yu X, Catalona WJ. Prostate specific 
antigen velocity in men with total prostate specific antigen less than 4 
ng/ml. J. Urol. 2007;78(6),2348-2353.
6. Döbrössy B, Koväcs A, Budai A, Comides A, Döbrössy L, Loeb S, i sur. 
The undesirable, psychological side effects of screening, (in Hungarian: 
A szüres nemkivänatos lelektani mellekhatäsai.) Orv.Hetil. 2007; 
148:1707-1711.
7. Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir D, i sur. 
Computer-aided ultrasonography (Histoscanning): A novel technology 
for locating and characterizing prostate cancer. BJU. 2008; 101:293-299.
TABLE 1
PSA in accordance with age (based on the studies of certain authors)
TABLICA 1.











Oesterling 2.5 3.5 4.5 6.5
Anderson 1.5 2.5 4.5 7.5
Reed 2.5 3.5 3.5 3.5
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PROSTATE SPECIFIČNI ANTIGEN: BLAGOSLOV ILI PROKLETSTVO?
Imre Romics
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SAŽETAK
Rano otkrivanje i dijagnoza poboljšavaju liječenje i preživljavanje kod pacijenata koji boluju od raka.
PSA je izvrsna urološka metoda koja može pomoći prilikom ranoga otkrivanja raka prostate povećavajući učinkovitost medicinsko­
ga liječenja ili nakon radikalne prostatektomije kako bi se provjerila uspješnost liječenja. S druge strane, PSA može dovesti do obavl­
janja nepotrebnih biopsija, kao i prouzročiti zabrinutost pacijenta, što također uključuje mnogo prednosti i mana. Moramo učiti i 
moramo biti upoznati s procjenom koncentracije PSA i različitih derivata PSA, kao što su brzina, gustoća i slobodna razina PSA.
PSA se ne tteba koiistiti samo kod svih pacijenata koji boluju od raka prostate, nego i za screening, u kombinaciji s rektalnim digi­
talnim i transrektalnim ultrazvučnim pregledom.
Ključne riječi: Prostata specifični antigen; Rak prostate - liječenje; Screening (probir)
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